The insider sales are immaterial relative to Vertex's market cap and likely reflect routine diversification or tax planning. No bearish signal. Monitor upcoming earnings or pipeline catalysts for directional moves; this cluster has no standalone trading implication.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $441.47entry
- T+1 · 6mo ago +1.13%α +3.73% · $446.47
- T+5 · 5mo ago +0.81%α +3.36% · $445.04
- T+20 · 4mo ago +19.61%α +21.24% · $528.04
- T+60 · 3mo ago +22.70%α +21.08% · $541.69
Price Chart
How similar events traded
Executive Summary
Two senior executives at Vertex Pharmaceuticals (EVP/CMO and EVP/Chief Legal Officer) sold a combined $1.25M in open-market sales over a 4-day window. The total value represents ~0.001% of Vertex's $107.9B market cap, a trivial amount. No insider buying occurred. The sales are routine in size and context, with no material signal for the stock.
Key Financial Metrics
Key Facts
- EVP and CMO Carmen Bozic sold 1,974 shares at $450.00 for $888,300 on 2026-05-29.
- EVP and Chief Legal Officer Joy Liu sold 828 shares at $439.91 for $364,245 on 2026-06-01.
- Total insider sales in the cluster: $1.25M, or ~0.001% of Vertex's $107.9B market cap.
- No insider purchases were reported in the cluster window.
- Recent 30-day insider activity shows 5 sells totaling $5.0M, consistent with routine portfolio diversification.
Financial Impact
Total insider sales of $1.25M, representing ~0.001% of market cap, economically negligible.
Risk Factors
- No material risk identified from this cluster, sales are trivial in size.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VRTX-1780517228070 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers